Equities Analysts Offer Predictions for AMAG Pharmaceuticals, Inc.’s FY2022 Earnings (AMAG)
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Research analysts at B. Riley issued their FY2022 earnings per share estimates for AMAG Pharmaceuticals in a note issued to investors on Tuesday. B. Riley analyst D. Buck forecasts that the specialty pharmaceutical company will post earnings per share of $1.78 for the year. B. Riley currently has a “Hold” rating and a $16.00 price target on the stock.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%.
AMAG Pharmaceuticals (AMAG) traded down $0.70 on Wednesday, reaching $13.25. The company had a trading volume of 797,989 shares, compared to its average volume of 825,392. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $25.20. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94. The firm has a market cap of $467.57, a price-to-earnings ratio of -2.18 and a beta of 0.79.
Several institutional investors and hedge funds have recently added to or reduced their stakes in AMAG. Rhumbline Advisers increased its position in shares of AMAG Pharmaceuticals by 2.3% during the second quarter. Rhumbline Advisers now owns 73,235 shares of the specialty pharmaceutical company’s stock valued at $1,348,000 after purchasing an additional 1,625 shares during the period. Legal & General Group Plc increased its position in shares of AMAG Pharmaceuticals by 10.5% during the second quarter. Legal & General Group Plc now owns 67,812 shares of the specialty pharmaceutical company’s stock valued at $1,247,000 after purchasing an additional 6,441 shares during the period. Principal Financial Group Inc. increased its position in shares of AMAG Pharmaceuticals by 2.2% during the second quarter. Principal Financial Group Inc. now owns 267,561 shares of the specialty pharmaceutical company’s stock valued at $4,923,000 after purchasing an additional 5,632 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of AMAG Pharmaceuticals during the second quarter valued at approximately $542,000. Finally, Schroder Investment Management Group increased its position in shares of AMAG Pharmaceuticals by 11.4% during the second quarter. Schroder Investment Management Group now owns 41,712 shares of the specialty pharmaceutical company’s stock valued at $761,000 after purchasing an additional 4,264 shares during the period.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.